Your browser doesn't support javascript.
loading
Inhibition of synucleinopathic seeding by rationally designed inhibitors.
Sangwan, Smriti; Sahay, Shruti; Murray, Kevin A; Morgan, Sophie; Guenther, Elizabeth L; Jiang, Lin; Williams, Christopher K; Vinters, Harry V; Goedert, Michel; Eisenberg, David S.
Afiliação
  • Sangwan S; Department of Biological Chemistry, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States.
  • Sahay S; UCLA-DOE Institute, University of California, Los Angeles, Los Angeles, United States.
  • Murray KA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, United States.
  • Morgan S; Department of Biological Chemistry, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States.
  • Guenther EL; UCLA-DOE Institute, University of California, Los Angeles, Los Angeles, United States.
  • Jiang L; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, United States.
  • Williams CK; Department of Biological Chemistry, Howard Hughes Medical Institute, University of California, Los Angeles, Los Angeles, United States.
  • Vinters HV; UCLA-DOE Institute, University of California, Los Angeles, Los Angeles, United States.
  • Goedert M; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, United States.
  • Eisenberg DS; MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.
Elife ; 92020 01 02.
Article em En | MEDLINE | ID: mdl-31895037
ABSTRACT
Seeding, in the context of amyloid disease, is the sequential transfer of pathogenic protein aggregates from cell-to-cell within affected tissues. The structure of pathogenic seeds provides the molecular basis and enables rapid conversion of soluble protein into fibrils. To date, there are no inhibitors that specifically target seeding of Parkinson's disease (PD)-associated α-synuclein (α-syn) fibrils, in part, due to lack of information of the structural properties of pathological seeds. Here we design small peptidic inhibitors based on the atomic structure of the core of α-syn fibrils. The inhibitors prevent α-syn aggregation in vitro and in cell culture models with binding affinities of 0.5 µM to α-syn fibril seeds. The inhibitors also show efficacy in preventing seeding by human patient-derived α-syn fibrils. Our results suggest that pathogenic seeds of α-syn contain steric zippers and suggest a therapeutic approach targeted at the spread and progression that may be applicable for PD and related synucleinopathies.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Parkinson / Alfa-Sinucleína / Agregação Patológica de Proteínas / Agregados Proteicos Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doença de Parkinson / Alfa-Sinucleína / Agregação Patológica de Proteínas / Agregados Proteicos Limite: Humans Idioma: En Revista: Elife Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos